Published on
November 1, 2024
- 10:00 GMT
Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial Targeting Residual Disease in AML
The novel study explores the effects of menin inhibition in acute myeloid leukemia with minimal residual disease as an endpoint. CAMBRIDGE, MA, UNITED STATES, November 1, 2024 /EINPresswire.com/ -- Break Through Cancer, a Boston-based cancer research …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
